Biotech Values

[poorgradstudent]

DNDN:

If the tidbit about them considering an acquisition is true, then what does that say about their "platform"?

Whatever happened to Neuvenge? Why haven't they been able to move any new antigen into the clinic?

I clearly have a bias here, but actions speak louder than words. I really think they lucked out with Provenge, and they know that it doesn't work they way they advertise it to work... and hence they're not exactly desperate to follow up on the platform.

That's my take. From a perpetual DNDN-bear.